Envestnet Asset Management Inc. Grows Position in Insulet Corporation $PODD

Envestnet Asset Management Inc. lifted its holdings in Insulet Corporation (NASDAQ:PODD) by 1.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,166 shares of the medical instruments supplier’s stock after buying an additional 2,514 shares during the period. Envestnet Asset Management Inc. owned approximately 0.19% of Insulet worth $42,039,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PODD. True Wealth Design LLC boosted its holdings in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 72 shares during the last quarter. Golden State Wealth Management LLC lifted its position in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new position in Insulet during the second quarter worth $35,000. Whittier Trust Co. of Nevada Inc. grew its holdings in Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 43 shares in the last quarter. Finally, Quent Capital LLC acquired a new stake in shares of Insulet in the 3rd quarter worth $49,000.

Insulet Price Performance

PODD stock opened at $252.41 on Wednesday. The business’s fifty day moving average price is $281.06 and its 200 day moving average price is $307.47. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $354.88. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $17.76 billion, a PE ratio of 73.16, a P/E/G ratio of 1.39 and a beta of 1.41.

Analyst Ratings Changes

Several research analysts have recently weighed in on PODD shares. Sanford C. Bernstein lowered their price target on shares of Insulet from $410.00 to $380.00 and set an “outperform” rating on the stock in a research report on Friday, January 9th. Leerink Partners lifted their target price on shares of Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. BTIG Research increased their price target on shares of Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a research note on Friday, November 21st. Truist Financial cut their price target on shares of Insulet from $412.00 to $390.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Finally, Royal Bank Of Canada lifted their price target on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Twenty analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.